JE: Human genetic studies provide strong target validation for the role of PCSK9 in modulating LDL cholesterol (LDL-C) levels and the risk of coronary heart disease (CHD). In 2006, Cohen and co ...
They are administered every two to four weeks, depending on LDL cholesterol response. Novartis upped the ante with Leqvio (inclisiran), an RNA interference drug that only needs to be given twice a ...